TY - JOUR
T1 - Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database
AU - the Japan Study Group of Prostate Cancer (J-CaP)
AU - Chikamatsu, Sotaro
AU - Shiota, Masaki
AU - Onozawa, Mizuki
AU - Hinotsu, Shiro
AU - Kitagawa, Yasuhide
AU - Sakamoto, Shinichi
AU - Kawai, Taketo
AU - Eto, Masatoshi
AU - Kume, Haruki
AU - Akaza, Hideyuki
N1 - Funding Information:
We thank Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript.
Publisher Copyright:
© 2021 The Japanese Urological Association
PY - 2021/9
Y1 - 2021/9
N2 - Objectives: The objectives of this study were to analyze the conditional survival and prognostic factors in androgen deprivation therapy for prostate cancer using the Japan Study Group of Prostate Cancer database. Methods: Data on patients treated with primary androgen deprivation therapy between 2001 and 2003 from a nationwide database of the Japan Study Group of Prostate Cancer were used. The conditional 5-year progression-free rate, cancer-specific survival and overall survival, as well as the conditional mortality owing to prostate cancer and other causes were calculated as per subgroups. Prognostic factors for progression-free rate, cancer-specific survival and overall survival at each time after androgen deprivation therapy initiation were calculated using the Cox proportional hazards model. Results: The conditional 5-year progression-free rate and cancer-specific survival, but not overall survival, gradually increased with time. The prognostic impact of stage IV characteristics (T4, N1 and M1) changed over time; however, the prognostic impact of the Gleason score remained unchanged. In the subgroup analysis, prostate-specific mortality risk reduced over time in patients with stage IV prostate cancer, whereas non-prostate cancer mortality increased over time in elderly patients. Conclusions: Information regarding conditional survival and mortality obtained in this study would provide a benchmark for physicians and cancer survivors.
AB - Objectives: The objectives of this study were to analyze the conditional survival and prognostic factors in androgen deprivation therapy for prostate cancer using the Japan Study Group of Prostate Cancer database. Methods: Data on patients treated with primary androgen deprivation therapy between 2001 and 2003 from a nationwide database of the Japan Study Group of Prostate Cancer were used. The conditional 5-year progression-free rate, cancer-specific survival and overall survival, as well as the conditional mortality owing to prostate cancer and other causes were calculated as per subgroups. Prognostic factors for progression-free rate, cancer-specific survival and overall survival at each time after androgen deprivation therapy initiation were calculated using the Cox proportional hazards model. Results: The conditional 5-year progression-free rate and cancer-specific survival, but not overall survival, gradually increased with time. The prognostic impact of stage IV characteristics (T4, N1 and M1) changed over time; however, the prognostic impact of the Gleason score remained unchanged. In the subgroup analysis, prostate-specific mortality risk reduced over time in patients with stage IV prostate cancer, whereas non-prostate cancer mortality increased over time in elderly patients. Conclusions: Information regarding conditional survival and mortality obtained in this study would provide a benchmark for physicians and cancer survivors.
UR - http://www.scopus.com/inward/record.url?scp=85106641149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106641149&partnerID=8YFLogxK
U2 - 10.1111/iju.14605
DO - 10.1111/iju.14605
M3 - Article
C2 - 34028097
AN - SCOPUS:85106641149
SN - 0919-8172
VL - 28
SP - 927
EP - 935
JO - International Journal of Urology
JF - International Journal of Urology
IS - 9
ER -